{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:49:31Z","timestamp":1777481371266,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10120-026-01727-w","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:08:40Z","timestamp":1773749320000},"page":"622-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402)"],"prefix":"10.1007","volume":"29","author":[{"given":"Ryo","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4954-5047","authenticated-orcid":false,"given":"Kazumasa","family":"Fujitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Akamaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Takachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Motoori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keijiro","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Komoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shugo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomono","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Masuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Tsujinaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1727_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1727_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000236018","volume":"77","author":"C Li","year":"2009","unstructured":"Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77:197\u2013204.","journal-title":"Oncology"},{"key":"1727_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/bjs.4164","volume":"90","author":"F Roviello","year":"2003","unstructured":"Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113\u20139.","journal-title":"Br J Surg"},{"key":"1727_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/jso.23301","volume":"107","author":"Y Iwasaki","year":"2013","unstructured":"Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107:741\u20135.","journal-title":"J Surg Oncol"},{"key":"1727_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","volume":"24","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24:492\u2013502.","journal-title":"Gastric Cancer"},{"key":"1727_CR6","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2006.10.4968","volume":"25","author":"JA Ajani","year":"2007","unstructured":"Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205\u20139.","journal-title":"J Clin Oncol"},{"key":"1727_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10120-019-01007-w","volume":"23","author":"D Takahari","year":"2020","unstructured":"Takahari D, Ito S, Mizusawa J, Katayama H, Terashima M, Sasako M, et al. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer. 2020;23:293\u20139.","journal-title":"Gastric Cancer"},{"key":"1727_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","volume":"4","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:501\u201310.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1727_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187\u201396.","journal-title":"Ann Surg"},{"key":"1727_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1727_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10120-011-0042-4","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113\u201323.","journal-title":"Gastric Cancer"},{"key":"1727_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10120-018-0884-0","volume":"22","author":"K Hosoda","year":"2019","unstructured":"Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, et al. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer. 2019;22:598\u2013606.","journal-title":"Gastric Cancer"},{"key":"1727_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653\u201360.","journal-title":"Br J Surg"},{"key":"1727_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00280-017-3404-8","volume":"80","author":"N Uemura","year":"2017","unstructured":"Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, Miyamoto H, et al. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer. Cancer Chemother Pharmacol. 2017;80:707\u201313.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1727_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00280-011-1701-1","volume":"69","author":"W Koizumi","year":"2012","unstructured":"Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 2012;69:407\u201313.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1727_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00280-013-2073-5","volume":"71","author":"M Hirakawa","year":"2013","unstructured":"Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol. 2013;71:789\u201397.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1727_CR17","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/annonc\/mdx236","volume":"28","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin\/S-1 and docetaxel\/cisplatin\/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017;28(8):1876\u201381.","journal-title":"Ann Oncol"},{"key":"1727_CR18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10120-015-0564-2","volume":"19","author":"T Voron","year":"2016","unstructured":"Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, et al. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19:1027\u201340.","journal-title":"Gastric Cancer"},{"key":"1727_CR19","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"issue":"3","key":"1727_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217\u201330.","journal-title":"N Engl J Med"},{"key":"1727_CR21","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J Clin Oncol. 2024;42:2961\u20135.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1727_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s10120-025-01608-8","volume":"28","author":"R Tanaka","year":"2025","unstructured":"Tanaka R, Endo S, Yamaguchi T, Miyagaki H, Kawada J, Omori T, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902). Gastric Cancer. 2025;28(4):662\u201372.","journal-title":"Gastric Cancer"},{"key":"1727_CR23","doi-asserted-by":"publisher","unstructured":"Endo S, Tanaka R, Yamaguchi T, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with largetype 3 or type 4 gastric cancer: fi nal outcomes of a multicenter, phase II study (OGSG 1902). Gastric Cancer.(Published online). https:\/\/doi.org\/10.1007\/s10120-025-01705-8","DOI":"10.1007\/s10120-025-01705-8"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01727-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01727-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01727-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:12:21Z","timestamp":1777385541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01727-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01727-w","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare their conflict of interest\/personal relationships, which may be considered as potential conflict of interests, in Supplementary Text 3.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were performed in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and its later versions. Written informed consent for inclusion in this study was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}